Substance / Medication

Alpha tocopherol succinate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Vitamin E supplementation in people with cystic fibrosis: A Cochrane review summary.
Dru Riddle J · Int J Nurs Stud · 2019
PMID: 29954583Meta-Analysis
The emerging role of immunothrombosis in paediatric conditions.
Franchi Thomas, Eaton Simon, De Coppi Paolo et al. · Pediatr Res · 2019
PMID: 30808021Meta-Analysis
Hemolytic uremic syndrome: differential diagnosis with the onset of inflammatory bowel diseases.
Bianchi Laura, Gaiani Federica, Vincenzi Francesca et al. · Acta Biomed · 2018
PMID: 30561409Meta-AnalysisFull text (PMC)
Vitamin E supplementation in people with cystic fibrosis.
Okebukola Peter O, Kansra Sonal, Barrett Joanne · Cochrane Database Syst Rev · 2017
PMID: 28262916Meta-AnalysisFull text (PMC)
Vitamin E supplementation in people with cystic fibrosis.
Okebukola Peter O, Kansra Sonal, Barrett Joanne · Cochrane Database Syst Rev · 2014
PMID: 25489958Meta-Analysis
Effects of vitamin E supplementation on glycaemic control in type 2 diabetes: systematic review of randomized controlled trials.
Suksomboon N, Poolsup N, Sinprasert S · J Clin Pharm Ther · 2011
PMID: 21198720Meta-Analysis
Risk of inadequate intakes of vitamins A, B1, B6, C, E, folate, iron and calcium in the Spanish population aged 4 to 18.
Serra-Majem L, Ribas L, Ngo J et al. · Int J Vitam Nutr Res · 2001
PMID: 11840835Meta-Analysis
ATRA promotes alpha tocopherol succinate-induced apoptosis in freshly isolated leukemic cells from chronic myeloid leukemic patients.
Kumar Surender, Khanduja Krishan Lal, Verma Neelam et al. · Mol Cell Biochem · 2008
PMID: 17874176Observational
[Inhibitory effect of alpha tocopherol succinate on fibroblast wound healing].
Pinilla I, Piazuelo E, Jiménez P et al. · Arch Soc Esp Oftalmol · 2000
PMID: 11151182Other

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Alpha tocopherol succinate (substance)
SNOMED CT
719899003
UMLS CUI
C0078375

Clinical Data

This intervention maps to 4 entities in the Healos knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.